Duke University and Affymetrix Initiate Five-Year Translational Research Collaboration
Affymetrix Inc. announced that it has entered into a five-year collaboration with Duke University to analyze genomic information across large patient samples. Under terms of the agreement, Duke researchers will use Affymetrix GeneChip(R) microarray technology to develop new applications for translational research projects. The initial projects will focus on cancer and cardiovascular disease.
Duke researchers will use Affymetrix' GeneChip HT (High-Throughput) System and arrays to perform large-scale clinical studies. The Affymetrix technology will enable them to more rapidly discover RNA and DNA patterns that can better classify, manage and treat complex diseases. As part of the agreement, Affymetrix will fund creative research and clinical projects that could lead to new genomic applications on the GeneChip platform, as well as novel diagnostics and screening tests.
Affymetrix collaborates with academic institutions and patient advocacy groups through the company's translational medicine program to develop more effective treatments. The translational medicine program complements the Powered by Affymetrix(TM) program, which enables companies to license GeneChip technology to develop innovative microarray products. This custom-designed technology is being used in many applications, including diagnostics, forensics, animal, industrial and food testing.
Other news from the department science
